STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #2817 by analyst upside · 2026-06-27
ASND
Ascendis Pharma A/S
Healthcare · Market Cap $17B · P/E 30.3x
ANALYST PRICE TARGET
+11.7%
implied upside to consensus target
Current Price $260.75
Consensus Target $291.15
Bull Target $347.4
Bear Target $247.72
Analysts Covering 18
ANALYST CONSENSUS — STRONG BUY
Strong Buy
13
Buy
4
Hold
1
Sell
0
52-Week Low $160.86
52-Week High $271.89
YTD Return +0.0%
FUNDAMENTALS
Market Cap $17B
P/E Ratio (TTM) 30.3x
Forward P/E 24.3x
EPS (TTM) $8.60
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $866M
Profit Margin 57.3%
52-WEEK RANGE
52-Week Low $160.86
52-Week High $271.89
Current Price $260.75
Bear Target $247.72
Bull Target $347.4
● Now $260.75 ● Target $291.15
TRADING DATA
Avg Volume 708K
YTD Return +0.0%
Analyst Count 18
Consensus Strong Buy
Upside to Target +11.7%
Last Updated 2026-06-27

ANALYST SUMMARY

Ascendis Pharma A/S (ASND) is currently trading at $260.75 with a Wall Street consensus price target of $291.15, implying potential upside of 11.7% over the next 12 months. 18 analysts currently cover ASND, with a consensus rating of Strong Buy — 94% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $347.4, while the most cautious has a target of $247.72.

ASND operates in the Healthcare sector with a market capitalisation of $17B. The stock is up 0.0% year-to-date and is currently trading near the upper end of its 52-week range of $160.86 – $271.89.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for ASND, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Citigroup ● Initiated
Buy 2026-05-19 Building track record
Evercore ISI Group — Reiterated
Outperform → Outperform 2026-05-15 Building track record
Barclays — Reiterated
Overweight → Overweight 2026-05-11 Building track record
Wells Fargo — Reiterated
Overweight → Overweight 2026-05-08 Building track record
B of A Securities — Reiterated
Buy → Buy 2026-04-16 Building track record
Wedbush reit
Outperform → Outperform 2026-04-09 Building track record
RBC Capital — Reiterated
Outperform → Outperform 2026-03-03 Building track record
Oppenheimer — Reiterated
Outperform → Outperform 2026-02-12 14% win rate (7 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
out of 100
Coverage depth
0/30
Consensus clarity
0/30
Vote unanimity
0/25
Rating stability
0/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call — not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →